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Abstract
Background: ATP binding is essential for the bioactivity of several growth factors including nerve growth factor,
fibroblast growth factor-2 and brain-derived neurotrophic factor. Vascular endothelial growth factor isoform 165
(VEGF-A165) induces the proliferation of human umbilical vein endothelial cells, however a dependence on ATP-
binding is currently unknown. The aim of the present study was to determine if ATP binding is essential for the
bioactivity of VEGF-A165.
Results: We found evidence that ATP binding toVEGF-A165 induced a conformational change in the secondary
structure of the growth factor. This binding appears to be significant at the biological level, as we found evidence
that nanomolar levels of ATP (4-8 nm) are required for the VEGF-A165-induced proliferation of human umbilical vein
endothelial cells. At these levels, purinergic signaling by ATP via P2 receptors can be excluded. Addition of alkaline
phosphate to cell culture lowered the ATP concentration in the cell culture medium to 1.8 nM and inhibited cell
proliferation.
Conclusions: We propose that proliferation of endothelial cells is induced by a VEGF-A165-ATP complex, rather
than VEGF-A165 alone.
Background
Vascular endothelial growth factor isoform VEGF-A165
is a primarily endothelial cell-specific mitogen that plays
a pivotal role in both vasculogenesis and angiogenesis
[1,2]. As a key regulator of neovascularization it pro-
motes embryonic development, wound healing and
female reproductive functions [3-5]. The function of
VEGF-A165 is associated with various medical disorders,
including tumor growth and metastasis, proliferative
retinopathies and inflammatory conditions such as rheu-
matoid arthritis and psoriasis [6-9].
There are at least eight different splice forms of the
VEGF-A gene with VEGF-A121,V E G F - A 165 and VEGF-
A189 being the most abundantly expressed in humans
[10-14]. All VEGF-A isoforms encode homodimeric
proteins that are glycosylated and secreted. Signaling
occurs through binding to the VEGF receptor 1 (Flt-1)
and 2 (KDR), two structurally related receptor tyrosine
kinases [15,16]. The splice forms of VEGF-A have vary-
ing affinity for heparan sulfate proteoglycans (HSPGs),
depending on the different heparin-binding domains
encoded by exons 6 and 7 [17-19]. The splice variant
VEGF-A165 is thought to be most effective mitogen due
to moderate heparin affinity encoded by the heparin
binding domain of exon-7. This domain also facilitates
the binding of VEGF-A165 to neuropilin 1, a co-receptor
which itself enhances binding of VEGF-A165 to VEGFR2
[20,21].
Binding to ATP has been shown to be important for a
number of growth factors, including nerve growth factor
(NGF), fibroblast growth factor-2 (FGF-2) and brain-
derived neurotrophic factor (BDNF) [22,23]. For BDNF,
at least, this appears to be mediated by covalent binding,
based on the results from mass spectrometry of BDNF-
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ques. Other growth factor-ATP complexes were not
stable under these ionization conditions, however have
been detected using a more gentle ionization method,
matrix assisted laser desorption/ionization (MALDI).
There is also evidence that the interaction of these
factors with ATP is important for their bioactivity. For
example, an interaction with ATP was proven to be a
prerequisite for the neuroprotective activity of NGF and
FGF2 [24,25]. Additionally, binding to ATP stabilized
FGF-2 against proteolytic cleavage and thermal dena-
turation [26]. Although in many cases the ATP binding
site and effect on protein structure is unkown, for NGF
and FGF-2 at least, the nucleotide binding is thought to
occur at the site of the heparin binding domain [25,27].
ATP levels are important for the nervous and vascular
systems and are known to act synergistically with
VEGF-A165 on endothelial cells [28-31]. In this study,
we investigated the hypothesis that the bioactivity of
VEGF-A165 is dependent on ATP-binding, using radiola-
beling and mass spectrometry techniques. To define its
biological relevance, we investigated the influence of the
extracellular ATP concentration on VEGF-A165-induced
proliferation of human umbilical vein endothelial cells
(HUVECs).
Methods
Materials
Adenosine-5’-triphosphate (ATP) disodium salt, alkaline
phosphatase (AP; from bovine intestinal mucosa), benza-
midine hydrochloride, dithiothreitol (DTT), heparin
sodium salt (from bovine intestinal mucosa), imadazole,
lysozyme (from chicken egg white), PMSF, plasmin
(from human plasma) and Triton
®-X 100 were pur-
chased from Sigma-Aldrich (Taufkirchen, Germany).
Sodium chloride and urea were from Merck (Darmstadt,
Germany), Tween
®20 and ethylenediamine tetraacetic
acid (EDTA) disodium salt from SERVA (Heidelberg,
Germany), Tris-HCl from USB (Cleveland, OH, USA)
and guanidine hydrochloride from GERBU (Gaiberg,
Germany).
Production and purification of recombinant human VEGF-
A165
Heterologous expression of the plasmid pET16b-
VEGFA165 in E. coli BL21(DE3) yielded recombinant
human VEGF-A165 (186 aa) comprising the N-terminal
His-tag sequence, GlyHis10, followed by a Factor Xa
cleavage site. Here, the translational product is referred
to as VEGF-A165. The expression of the plasmid was
performed as described previously [27]. It resulted in
the formation of inclusion bodies which represented the
primary source of the target protein. They were isolated
and solubilized. To that end, frozen cell pellets of E. coli
BL21(DE3) pET16b-VEGFA165 were resuspended
(Ultraturrax T 25; Jahnke & Kunkel, Staufen, Germany)
in lysis buffer (0.1 M Tris-HCl pH 7.5, 5 mM EDTA,
150 mM NaCl) containing lysozyme (0.1% (w/v)), phe-
nylmethylsulfonyl fluoride and benzamidine (1 mM
each). Following sonication on ice Triton
®-X 100 (2%
(w/v)), MgCl2 (1 mM) and DNase I (1 μL/mL) were
added for 30 min of incubation at 25°C. Subsequently,
inclusion bodies were collected by centrifugation (47.800
× g, 15 min, 4°C) and washed twice with buffer (0.1%
(v/v) Tween
® 20, 150 mM NaCl) and double-destilled
water (ddH2O) prior to solubilisation in 8 M urea, 50
mM Tris-HCl (pH 8) and 20 mM 2-mercapotethanol.
VEGF-A165 was purified from this solution by immobi-
lized metal ion chromatography. For that purpose, solu-
bilized inclusion bodies were applied to an Econo-
column (BioRad, Hercules, CA, USA) filled with Ni
2
+-nitrilotriacetic acid agarose (Qiagen, Hilden, Ger-
many), washed and eluted using 250 mM imadazole
according to the manufacturer’s instructions. For rena-
turation, pooled fractions of VEGF-A165 were reduced
with DTT (20 mM) and dialysed against renaturation
buffer (500 mM guanidine hydrochloride, 100 mM Tris-
HCl pH 9.0, 2 mM EDTA, cysteine/cystine redox system
(5:1 ratio; 5 mM cysteine, 1 mM cystine)). Finally,
refolded, dimeric VEGF-A165 was dialyzed against 100
mM sodium acetate buffer (pH 5) and concentrated
using Amicon Ultra centrifugal filter devices (10 kDa
molecular weight cut-off; Millipore, Bedford, MA, USA).
Labeling of VEGF-A165 with [g-
32P]ATP and [a-
32P]ATP
For labeling, 3 μgV E G F - A 165 (unless otherwise noted)
was incubated with 5 μCi each of [g-
32P]ATP or [a-
32P]
ATP (Hartmann Analytic, Braunschweig, Germany) and
combined with 0.01 mM non-radioactive ATP (option-
ally containing 0.1 mM MgCl2). Incubation was per-
formed in 25 mM Tris-HCl (pH 7.5, total volume 15
μL, 37°C, 15 min). For treatment of labeled VEGF-A165
with heparin (1, 10 or 100 μg/mL), sodium chloride
(100 mM) or AP (300 ng/15 μL) incubation was contin-
ued for additional 15 min upon addition of each com-
pound. Proteins were separated by reducing sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE; 17.5%). Minigels were vacuum-dried. Radiolabel-
ing was detected using a BAS-1800 II reader and BAS-
MS 2325 imaging plates (Fujifilm, Tokyo, Japan) and
analyzed with AIDA Image Analyzer software (version
3.21.001, Raytest GmbH, Straubenhardt, Germany).
Plasmin digestion of VEGF-A165 labeled with ATP
2 μg( 6μM) VEGF-A165 was incubated in the presence
or absence of 20 μM ATP in 25 mM Tris-HCl (pH 7.5)
at 37°C for 15 min. Subsequently, 300 ng plasmin was
added for proteolytic cleavage and incubation was
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non-digested growth factor, 2 μgV E G F - A 165 were trea-
ted in the same way except that ATP and plasmin were
omitted. Protein fragments were separated by reducing
SDS-PAGE (17.5%) and visualized by silver staining [32].
Circular dichroism (CD) spectroscopy
Far-UV CD spectra (195-250 nm) were recorded at 100
nm/min using a Jasco-J600 spectropolarimeter and a 0.1
cm sample cell (25°C, 4 accumulations each). Data point
resolution and bandwidth were set to 1 nm, sensitivity
to 50 mdeg. Samples containing 40 μMV E G F - A 165
were pre-incubated with or without a twofold excess of
ATP (80 μM) in 25 mM Tris-HCl (pH 7.5, 37°C, 15
min). Final protein CD spectra were background-cor-
rected with regard to absorption caused by ATP and
buffer components. Data were evaluated using J-700 for
Windows Standard Analysis software.
MALDI-TOF MS
For detection of the VEGF-A165-ATP complex, MALDI-
TOF MS was performed according to König et al. [23]
with slight modifications. VEGF-A165 and its complexes
were purified by reversed phase chromatography using
C18-ZipTip pipet tips (Millipore, Bedford, MA, USA).
Pipet tips were washed with elution solvent (80% metha-
nol, 0.1% acetic acid) and equilibrated with aqueous sol-
vent (5% methanol, 0.1% acetic acid) before use. For
purification, samples containing 27.5 μMV E G F - A 165,
optionally combined with ATP (30 μM) and MgCl2 (60
μM), were applied, rinsed with aqueous solvent and
eluted into 5 μL of elution solvent. Purified samples (0.5
μL) were spotted onto a MALDI-target coated with 0.5
μL of 1% sinapinic acid in acetone. Subsequently, 0.5 μL
of 1% sinapinic acid in 40% acetonitrile was added.
Spectra were obtained with MALDImicroMX (Waters
Corp., Manchester, UK).
Cell proliferation assay
HUVECs (Promocell, Heidelberg, Germany) were seeded
in 96-well plates at 8 × 10
4 cells/well containing 100 μL
of Endothelial Cell Growth Medium with supplements
(EGM; Promocell, Heidelberg, Germany). Seeded
HUVECs were cultured under standard conditions
(humidified atmosphere, 5% (v/v) CO2, 37°C) for 24 h
before EGM was replaced by 100 μL Endothelial Cell
Basal Medium (EBM; Promocell, Heidelberg, Germany)
containing 0.1% (w/v) bovine serum albumin (BSA).
After 1 h of incubation, media were replaced once more
by 100 μL EBM containing VEGF-A165 (20 ng/mL)
instead of BSA. In addition, AP (Sigma-Aldrich, Tauf-
kirchen, Germany) was applied to selected samples at
40, 80 or 160 ng/mL along with thegrowth factorand
incubation was continued for 48 h. Subsequently, cell
culture media were taken from separate samples treated
in the same manner for measurement of extracellular
ATP.
Finally, proliferation of HUVECs was determined
using the CellTiter 96
® Aqueous One Solution Cell Pro-
liferation Assay kit (Promega, Mannheim, Germany)
according to the manufacturer’s instructions. To that
end, 20 μL of CellTiter 96
® Aqueous One Solution was
added to each well to be incubated for additional 3 h.
T h en u m b e ro fv i a b l ec e l l sw a sd i r e c t l yp r o p o r t i o n a lt o
the absorbance of a colored formazan product deter-
mined colorimetrically (Lambda Scan, MWG Biotech,
Ebersberg, Germany) at 490 nm. Values are presented
as means ± standard deviation (SD; n = 9).
Luminometric measurement of extracellular ATP
Extracellular ATP was determined in cell-free samples
of cell culture media (80 μLe a c h )e m p l o y i n gt h eA T P
Kit SL (sensitivity: 10
-6-10
-12 mol/L; BioThema, Handen,
Sweden) according to the manufacturer’s instructions.
The bioluminescent reaction is based on the luciferase-
catalyzed oxidation of luciferin in the presence of oxy-
gen and ATP. Besides AMP, pyrophosphate and carbon
dioxide, oxiluciferin is produced emitting light at 560
nm to be measured luminometrically. Light emission is
proportional to the amount of ATP and was measured
in a two-step procedure using an FB 12 Single tube
Luminometer (Berthold Detection Systems, Pforzheim,
Germany). First, the light intensity of the samples (Ismp)
was quantified as relative light units/second (RLU/s).
Then, an internal ATP standard (final concentration 10
μM) was added to each sample and light intensity was
quantified again to give Ismp+std. This procedure allowed
for the conversion of light intensity (RLU/s) to concen-
tration of ATP (mol/L) by the following equation:
ATPsmp = 12.5 · (10−7 · Ismp):( I smp+std − Ismp).
The assay was performed in triplicate.
Statistical analysis
Data are expressed as means ± SD based on one-way
analysis of variance (ANOVA) followed by Scheffé’s test.
A probability value (P) of less than 0.01 was considered
statistically significant. Figure legends specify statistically
significant differences between experimental groups at
probability values of p < 0.01 and p < 0.001. Analysis
was performed using WinSTAT.
Results
Binding of ATP to VEGF-A165
In order to evaluate the binding of ATP to VEGF-A165,
VEGF-A165 was radiolabeled by [g-
32P]ATP and [a-
32P]
ATP. The use of [g-
32P ] A T Pa sw e l la s[ a-
32P]ATP
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VEGF-A165 and autophosphorylation. The influence of
divalent cations (Mg
2+) was also tested. Signal is
detected for both [g-
32P]ATP- and [a-
32P]ATP-labeled
growth factor independently of the presence of Mg
2+
(Figure 1). ATP appeared to be bound to growth factor
by non-covalent interaction via the phosphate residues
of the nucleotide [23,25,27]. In contrast to a covalent
modification, an ionic interaction can be influenced by
an increase in ionic strength. Labeling of VEGF-A165
with [g-
32P]ATP and [a-
32P]ATP, respectively, was sup-
pressed by 100 mM NaCl added to the reaction mixture
prior to the nucleotides (Figure 2). Once the complex
had formed, however, it proved to be fairly resistant to
the salt concentration.
VEGF-A165 contains a heparin-binding domain which is
critical for its mitogenic activity and storage in the extra-
cellular matrix via HSPGs [33]. Interestingly, heparin
affected binding of ATP to FGF-2 due to overlapping
binding sites [27]. Competition experiments revealed that
heparin also interfered with the binding of ATP to VEGF-
A165.1 0μg/mL heparin added to the reaction mixture
prior to [g-
32P]ATP reduced radiolabeling of VEGF-A165
markedly (Figure 3A). 100 μg/mL heparin inhibited [g-
32P]
ATP binding to the mitogen completely. However, when
[g-
32P]ATP was added to the reaction mixture prior to
heparin (100 μg/mL), only a slight decrease in radiolabel-
ing of VEGF-A165 occurred (Figure 3B, lane 3).
MALDI-TOF MS of the VEGF-A165-ATP complex
MALDI-TOF MS was performed employing soft condi-
tions as described previously [23]. This approach was
suitable for the detection of labile nucleotide-protein
complexes. Sample preparations using low-acidic
reversed phase chromatography and acid-free matrix
assisted in retaining the non-covalent interaction. The
measurements were performed using the high-mass
detector in order to observe the VEGF-A165 dimer as
the bioactive species present in vivo [1].
The incubation of VEGF-A165 with ATP (507.2 g/mol)
caused considerable peak broadening as compared to
pure VEGF-A165 (21673 Da) (Figure 4). The shift in
mass corresponded to the addition of one molecule of
ATP per molecule of growth factor and did not differ
when Mg
2+ was added to the incubation mixture. The
dimer was also affected by ATP, but the number of
bound ATP molecules could not be clearly defined due
to low signal intensity.
ATP induces a conformational change of VEGF-A165
Far-UV CD spectroscopy was carried out in order to
investigate a putative effect of ATP binding on the second-
ary structure of VEGF-A165. Thus, the CD of VEGF-A165
Figure 1 Labeling of VEGF-A165 with [g-
32P]ATP and [a-
32P]ATP.
VEGF-A165 (2 μg) was incubated with radioactive ATP (5 μCi) in Tris-
HCl (pH 7.5) at 37°C. MgCl2 (0.1 mM) was added prior to ATP (+).
After 15 min of incubation SDS-PAGE and autoradiography were
performed.
Figure 2 Effect of increased ionic strength on labeling of
VEGF-A165 with [g-
32P]ATP and [a-
32P]ATP. VEGF-A165 (3 μg) was
incubated with radioactive ATP (5 μCi) in Tris-HCl (pH 7.5) at 37°C
for 30 min. NaCl (100 mM) was added at times (t) indicated.
Figure 3 Competition of heparin and [g-
32P]ATP for binding to
VEGF-A165. VEGF-A165 (3 μg) was labeled with [g-
32P]ATP (5 μCi) in
Tris-HCl (pH 7.5) at 37°C for 30 min. (A) Heparin was added prior to
ATP to give final concentrations of 1 to 100 μg/mL. (B) Heparin was
added at a fixed concentration of 100 μg/mL and times (t)
indicated.
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ATP. The graph obtained for (His)10-tagged rhVEGF-A165
(Figure 5) was similar to that reported in the literature for
untagged rhVEGF-A165 reflecting a typical graph of a pro-
tein rich in b-structure [34,35]. The latter accounts for
about 40% of the secondary structure of rhVEGF-A165.A
first maximum close to the base level below 200 nm fell to
a minimal molar ellipticity at 207 nm and rose again to a
second maximum at 250 nm. In contrast, the CD spectrum
of VEGF-A165 with ATP exhibited a significant decrease in
molar ellipticity towards the base level above 200 nm, espe-
cially at 207 nm (Figure 5, dashed line). This result sug-
gested reduced b-sheet content in the secondary structure
of the growth factor compensated for by an increase in
random coil structure.
Binding of ATP does not protect VEGF-A165 from plasmin
cleavage
The serine protease plasmin cleaves VEGF-A165 solely at
the Arg
110-Ala
111 bond yielding VEGF-A110 and an N-
terminal fragment consisting of 55 residues including
the heparin-binding domains [33]. Compared to VEGF-
A165, VEGF-A110 exhibits a markedly reduced mitogenic
activity on HUVECs. In the case of FGF-2, ATP binding
protected effectively against proteolytic digestion by pro-
teases including plasmin [26]. This was not true for
VEGF-A165 (Figure 6). Plasmin digestion of VEGF-A165
and VEGF-A165 pre-incubated with ATP generated a
most abundant cleavage product of 15 kDa in all sam-
ples which corresponded to the molecular mass of (His)
10-tagged VEGF-A110.
Mitogenic activity of VEGF-A165 on HUVECs requires ATP
NGF and FGF-2 protected cultured neurons against
damage by staurosporine only if ATP at concentrations
above 1 nM were present in the culture medium
[24,25]. In order to investigate this effect for VEGF-
A165, we compared the proliferative effect of VEGF-A165
in untreated cultures of HUVECs with that at reduced
ATP level. ATP levels in the cell culture medium were
lowered by AP and measured luminometrically. AP
dephosphorylated both free ATP and [g-
32P]ATP or [a-
32P]ATP bound to VEGF-A165 (Figure 7).
Figure 4 MALDI-TOF spectrum overlay of VEGF-A165 and the
VEGF-A165-ATP complex. VEGF-A165 (27.5 μM), ATP (30 μM ATP).
ATP (507.2 g/mol) causes peak broadening due to complex
formation with VEGF-A165. The further addition of 60 μMM g
2+ has
no measurable impact on the spectrum (data not shown).
Figure 5 ATP induces a conformational change in the
secondary structure of VEGF-A165. Far-UV CD spectra were
recorded of VEGF-A165 (40 μM) pre-incubated without or with ATP
(80 μM). Pre-incubation was performed in Tris-HCl (pH 7.5) at 37°C
for 15 min.
Figure 6 Proteolytic cleavage of ATP-labeled and unlabeled
VEGF-A165 by plasmin. VEGF-A165 (6 μM) was preincubated in Tris-
HCl (pH 7.5) without or with ATP (20 μM) at 37°C. After 15 min of
pre-incubation, 300 ng of plasmin was added to one sample (lane
3) and incubation of all samples was continued for an additional
120 min. Reaction products were visualized by SDS-PAGE and silver
staining.
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HUVECs in the positive control significantly (Figure 8A,
VEGF). 40 ng/mL AP reduced eATP to 3.82 nM (positive
control: 8.30 nM) which did not impair the mitogenic
activity of VEGF-A165. However, higher concentrations of
AP (80 ng/mL, 160 ng/mL) inhibited HUVEC prolifera-
tion by VEGF-A165 due to lowering of ATP levels to 1.84
nM and 0.21 nM, respectively (Figure 8B), in the cell cul-
ture medium. AP (160 ng/mL) added without exoge-
neous VEGF-A165 did not influence HUVEC viability
despite reducing eATP effectively to 0.26 nM. In line
with the data obtained for NGF and FGF-2, these results
proved that VEGF-A165 required eATP in the low nano-
molar range to act mitogenically on HUVECs.
Discussion
In previous work it has been demonstrated that growth
factors such as NGF, BDNF and FGF-2 bind ATP and
form non-covalent nucleotide-protein complexes [22,23]
which are essential for neuroprotective activity in vitro
[24,25]. In the case of FGF-2, binding of ATP also
imparts enhanced proteolytic and thermal resistance
[26]. In the present study, we detected binding of ATP
to VEGF-A165, the predominant growth factor involved
in neovascularization. Both radiolabeling (Figure 1) and
mass spectrometry (Figure 4) analyses suggested that
ATP bound to VEGF-A165 is independent of Mg
2+-ions.
The VEGF-A165-ATP complex appears to be extremely
stable, remaining intact after denaturing SDS-PAGE,
solid phase extraction and mass spectrometry techni-
ques. In addition, an increase in ionic strength caused
only a minor dissociation of the complex (Figure 2).
The most physiologically important form of ATP is
thought to be the ATP/Mg
2+-complex, which is the pre-
dominant form of the nucleotide in tissue. Although our
mass spectrometry analyses provide strong evidence that
ATP bound to VEGF-A165 independently of Mg
2+-ions,
labeling of VEGF-A165 with [g-
32P]ATP could also be
observed with 0.1 mM MgCl2 in the reaction buffer
(data not shown). This is also true for labeling of the
growth factor NGF [25]. Such ATP/Mg
2+/growth factor
complexes were identified by MALDI-TOF analysis of
the growth factors FGF2 and NGF recently [23]. Radi-
olabeling of NGF with ATP is also possible in buffers
containing Ca
2+,M g
2+,M n
2+ or Ni
2+, respectively [25].
Taken together, this indicates that VEGF-A165 also
forms a complex with ATP at physiological Mg
2
+-concentrations.
Additionally, the recently discovered stabilization of
FGF2 by ATP is also present when using Mg
2+-ions
[36]. This observed stabilizing effect of ATP on the
growth factor is present at Mg
2+ concentrations of 0.1
mM. This indicates that under these conditions ATP/
Mg
2+ binds to FGF2 and that this physiological ATP/
cation complex protects FGF2 against degradation, too.
The effect of ectonucleases on the VEGF-A165-ATP
complex also remains unknown. Our results suggest
that the ATP bound to VEGF-A165 was not only com-
pletely susceptible to cleavage by alkaline phosphatase
Figure 7 AP hydrolyzes [g-
32P]ATP and [a-
32P]ATP bound to
VEGF-A165. VEGF-A165 (15 μM) was labeled with radioactive ATP (5
μCi) in Tris-HCl (pH 7.5) at 37°C for 15 min. After labeling (t = 15
min), 300 ng of AP was added (lane 3 and 4). Incubation of all
samples was continued for an additional period of 15 min followed
by SDS-PAGE and autoradiography.
Figure 8 VEGF-A165 fails to induce proliferation of HUVECs at
low extracellular ATP concentrations. (A) HUVECs were cultured
in serum-free EBM (C) or serum-free EBM containing VEGF-A165 (20
ng/mL), AP (160 ng/mL) or VEGF-A165 (20 ng/mL) combined with
AP at concentrations increasing from 40 ng/mL to 160 ng/mL. After
48 h of incubation CellTiter 96
® Aqueous One Solution Cell
Proliferation Assay was performed. The absorption of a colored
formazan product measured colorimetrically is proportional to the
number of viable cells. Values are presented as means ± SD (n = 9).
***p < 0.001 vs. C,
###p < 0.001 and
##p < 0.01 vs. VEGF (ANOVA,
Scheffé’s test). (B) ATP concentrations corresponding to (a) were
analyzed luminometrically (n = 3) in the HUVEC culture medium
after 48 h of incubation.
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(data not shown).
Our results are consistent with the theory that growth
factors bind ATP despite the absence of classic ATP
binding site. Nevertheless, NGF, FGF-2 and VEGF-A165
contain heparin binding domains, characterized by clus-
ters of basic residues [37-39], which may interact with
the negatively charged phosphate residues of ATP. The
removal of these basic residues by site-directed muta-
genesis of NGF and FGF-2 has been shown to drastically
reduced both ATP binding and neuroprotective activity
[25,27,40]. Heparin has been shown to suppress the
binding of ATP to VEGF-A165 (Figure 3), however does
not cause the existing VEGF-A165-ATP complex to dis-
sociate. Nevertheless, the competition between ATP and
heparin for binding to VEGF-A165 is likely to effect the
interaction with the VEGF receptor or storage in the
extracellular matrix.
Our results strongly suggest that ATP binding induces
a conformational change in the secondary structure of
VEGF-A165. We propose that this conformational
change is responsible for the increased bioactivity of the
VEGF-165-ATP complex, resulting in improved ligand-
receptor interaction (Figure 5). The location at which
ATP binds VEGF-A165, as well as the exact nature of
the conformational change remains unknown.
Brandner et al. [34] demonstrated that heparan sulfate
induced a conformational change in glycosylated VEGF-
A165 but not in the non-glycosylated form. In addition,
they showed that heparin stabilized both glycosylated and
non-glycosylated VEGF-A165 against chaotropic or thermal
denaturation without inducing any conformational change.
This implies that the competition of ATP and heparin
(HSPGs) for binding to the mitogen is of biological rele-
vance. Further studies have to be undertaken in order to
define exactly where ATP is bound providing a basis for
elucidating putative complex-receptor interactions.
We found no evidence that ATP binding protects
VEGF-A165 against plasmin cleavage (Figure 6), as pre-
viously suggested for FGF-2 [26]. We therefore propose
that the biological activity of the VEGF-A165-ATP com-
plex is due to improved receptor binding, and not due
to increased stability of the growth factor. Supporting
this theory, VEGF-A165 failed to induce HUVEC prolif-
eration when the ATP concentration in the cell culture
media was too low (Figure 8). This result corresponded
to the minimal concentration of eATP required for the
neuroprotective activity of NGF and FGF-2, which was
determined to be approximately 1 nM [24,25].
In our cell culture experiments, alkaline phosphatase
was required to lower the concentration of ATP to levels
that affected cell proliferation. It is feasible that high con-
centrations of alkaline phosphatase had independent
effects, and we cannot discount the possibility of minor
contamination with proteases. Alkaline phosphatase
added without exogeneous VEGF-A165 did not influence
HUVEC viability (despite reducing eATP levels to 0.26
nM; Figure 8). Therefore, we believe side effects of alka-
line phosphates at these concentrations are unlikely. This
is in line with investigations with other growth factors
like FGF2 [24] and NGF [25] that demonstrated similar
results when using alkaline phosphatase to lower eATP-
concentrations.
A completely different observation was made when
using another growth factor, granulocyte colony stimulat-
ing factor (GCSF). This factor does not bind ATP and the
neuroprotective activity of GCSF is not influenced by
degradation of extracellular ATP by alkaline phosphatase
(data not shown). This is in contrast to the situation with
the ATP-binding growth factors FGF2 and NGF, where
an extracellular ATP-concentration above about 1 nM is
essential for the neuroprotective activity of these growth
factors [24,25]. However, this is plausible in the context
of our hypothesis that ATP-growth factor interaction is
essential for the activity of ATP-binding growth factors
but not important for non-ATP-binding growth factors
like GCSF. It is therefore reasonable to assume that the
observed inhibition of HUVEC proliferation by VEGF-
A165 was due to the low ATP levels caused by alkaline
phosphatase, which prevented the formation of the pre-
sumed biologically active VEGF-A165-ATP complex.
It is known that eATP can act synergistically with
angiogenic growth factors including VEGF-A165 via P2Y
receptor signaling [30]. Even in the absence of VEGF-
A165, the nucleotide itself is capable of P2Y1/2-VEGFR2
transactivation, inducing endothelial cell proliferation
[31,41]. Given that activation of P2X and P2Y receptors
requires eATP in the micromolar range [42], isolated
effects of eATP mediated by purinergic receptor signal-
ing are unlikely to contribute to the experimental results
obtained from our model (Figure 8). We have clearly
shown that ATP is tightly bound to VEGF-A165 and a
critical concentration of ATP above 1.8 nM is required
for bioactivity. Based on these results, the VEGF-A165-
ATP complex and not VEGF-A165 by itself appears to
b et h ea c t i v el i g a n dc a u s i n gt h ep r o l i f e r a t i v ee f f e c t s
under cell culture conditions. Both VEGF-A165-ATP
complex formation and the putative interaction with its
receptor remain to be elucidated in vivo.
Conclusions
For the first time we provided ample evidence that ATP
binds to VEGF-A165. Binding of ATP most likely
involves basic residues within the heparin binding
domain and constitutes a prerequisite for the prolifera-
tive activity of VEGF-A165.
Gast et al. BMC Biochemistry 2011, 12:28
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